NovoCure Limited reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 133.78 million compared to USD 128.43 million a year ago. Net loss was USD 47.08 million compared to USD 37.3 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.36 a year ago.
For the full year, sales was USD 509.34 million compared to USD 537.84 million a year ago. Net loss was USD 207.04 million compared to USD 92.53 million a year ago. Basic loss per share from continuing operations was USD 1.95 compared to USD 0.88 a year ago.